MEPE antibody (AA 201-300) (Cy5)
Quick Overview for MEPE antibody (AA 201-300) (Cy5) (ABIN1418058)
Target
See all MEPE AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 201-300
-
Cross-Reactivity
- Mouse
-
Predicted Reactivity
- Human
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human MEPE
-
Isotype
- IgG
-
-
-
-
Application Notes
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Expiry Date
- 12 months
-
-
- MEPE (Matrix Extracellular phosphoglycoprotein (MEPE))
-
Alternative Name
- MEPE
-
Background
-
Synonyms: Matrix extracellular phosphoglycoprotein, MEPE, MEPE_HUMAN, OF45, Osteoblast/osteocyte factor 45.
Background: MEPE is a 525 amino acid extracellular matrix protein. Expressed in osteocytes and brain, MEPE is a regulator of bone metabolism that is thought to mediate mineralization and demineralization within the osteocyte microenvironment. MEPE contains an RGD cell-attachment motif and shares molecular similarities with several dentin-bone extracellular matrix RGD-containing phosphoglycoproteins, including OPN (osteopontin) and DSP (dentin sialophosphoprotein). Via its ability to control bone mineralization, MEPE is associated with various developmental events such as skeletogenesis, bone regeneration and odontogenesis. MEPE is secreted in hypophosphatemic osteomalacia tumors, suggesting a possible role in the pathophysiology of bone-related cancers.
-
Gene ID
- 56955
Target
-